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Abstract
Background: The ProtecT trial reported intention-to-treat analysis ofmenwith localised
prostate cancer randomly allocated to active monitoring (AM), radical prostatectomy,
and external beam radiotherapy.
Objective: To report outcomes according to treatment received in men in randomised
and treatment choice cohorts.
Design, setting, and participants: This study focuses on secondary care. Men with
ost
l cclinically localised pr
in the treatment tria
y Drs. Donovan, Hamdy, Lane, Metcalfe, and Neal contributed equally.
z Sadly, Professor Doug Altman passed away while this paper was being completed.
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under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncate cancer at one of nine UK centres were invited to participate
omparing AM, radical prostatectomy, and radiotherapy.opean Association of Urology. This is an open access article
-nd/4.0/).
Intervention: Two cohorts included 1643 men who agreed to be randomised and
997 who declined randomisation and chose treatment.
Outcome measurements and statistical analysis: Analysis was carried out to assess
mortality, metastasis and progression and health-related quality of life impacts on
urinary, bowel, and sexual function using patient-reported outcome measures. Anal-
ysis was based on comparisons between groups defined by treatment received for
both randomised and treatment choice cohorts in turn, with pooled estimates of
intervention effect obtained using meta-analysis. Differences were estimated with
adjustment for known prognostic factors using propensity scores.
Results and limitations: According to treatment received, more men receiving AM
died of PCa (AM 1.85%, surgery 0.67%, radiotherapy 0.73%), whilst this difference
remained consistent with chance in the randomised cohort (p = 0.08); stronger
evidence was found in the exploratory analyses (randomised plus choice cohort)
when AM was compared with the combined radical treatment group (p = 0.003).
There was also strong evidence that metastasis (AM 5.6%, surgery 2.4%, radiotherapy
2.7%) and disease progression (AM 20.35%, surgery 5.87%, radiotherapy 6.62%) were
more common in the AM group. Comparedwith AM, therewere higher risks of sexual
dysfunction (95% at 6 mo) and urinary incontinence (55% at 6 mo) after surgery, and of
sexual dysfunction (88% at 6 mo) and bowel dysfunction (5% at 6 mo) after radiother-
apy. The key limitations are the potential for bias when comparing groups defined by
treatment received and changes in the protocol for AM during the lengthy follow-up
required in trials of screen-detected PCa.
Conclusions: Analyses according to treatment received showed increased rates of
disease-related events and lower rates of patient-reported harms in menmanaged by
AM compared with men managed by radical treatment, and stronger evidence of
greater PCa mortality in the AM group.
Patient summary: More than 95 out of every 100 men with low or intermediate risk
localised prostate cancer do not die of prostate cancer within 10 yr, irrespective of
whether treatment is bymeans ofmonitoring, surgery, or radiotherapy. Side effects on
sexual and bladder function are better after active monitoring, but the risks of
spreading of prostate cancer are more common.
© 2019 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Clinically localised prostate cancer detected by prostate-
specific antigen (PSA) testing is a common problem with
164 690men in the USAdiagnosed in 2017 and 29 430 dying
of the disease [1]. Management of men with low- or
intermediate-risk disease [2] remains problematic for
patients and clinicians [2,3]. It is recognised that many
men with low- or intermediate-risk disease do not
benefit from immediate radical intervention, although
recent studies have shown improved future outcomes in
high-risk men [4].
The UK National Institute for Health Research, Health
Technology Assessment ProtecT study compared active
monitoring (AM), surgery (radical prostatectomy [RP]), and
radiotherapy (RT) for men aged 50–69 yr with localised
prostate cancer detected through community-based PSA
testing [5,6]. All 2664 men eligible to participate in the
randomised controlled trial (RCT) were followed up
identically [6]. A total of 1643 (62%) men agreed to be
randomised (“randomised cohort”), and 997 men declined
randomisation and chose treatment (“treatment choice
cohort”) [7]. Of the 1643 randomised, 22% did not receive
their allocated treatment (16% AM, 28% RP, and 23% RT) [7].
Intention-to-treat (ITT) analysis gives unbiased esti-
mates of differences in outcome between allocated treat-
ments, but may underestimate differences between patient
groups defined by treatment received [8–10]. This paper
presents an analysis of groups defined according totreatment received in the randomised and treatment choice
cohorts. Such analyses can be informative to individual
patients considering which treatment to undergo, but
groups defined by treatment received may not be compa-
rable, as patientswith less favourable prognosesmayopt for
more radical treatment, resulting in “confounding by
indication”. The analysis presented here attempted to
control that confounding using a propensity score approach.
2. Patients and methods
2.1. Study design and participants
In brief, men with clinically localised prostate cancer at one of nine UK
centreswere invited toparticipate in the treatmenttrialcomparingAM,RP,
and RT [11]. Approval was obtained from the UK Trent Multicentre Ethics
Committee (01/4/025; trial registration ISRCTN20141297, NCT02044172).
The primary analysis was reported at 10-yr follow-up [2,3,11].
2.2. Interventions, definitions of “treatment received”, and
follow-up
Men managed by AM had PSA measured 3 monthly in the 1st year and
6–12 monthly thereafter. An increase of 50% or more in PSA over a
12-mo period triggered a clinical review. During RP, men with a PSA
level of 10 mg/l or a Gleason score of 7 underwent lymphadenec-
tomy. Adjuvant RT was considered for positive margins or extra-
capsular disease. The RT protocol included neoadjuvant androgen
deprivation therapy (ADT) for 3–6 mo before and concomitantly
with three-dimensional conformal RT (74 Gy in 37 fractions).
Table 1 – Baseline characteristics of men in the randomised cohort
and treatment choice cohort, in groups defined by the completion
of curative surgery or radiotherapy, or remaining on protocol
active monitoring for 12 mo after diagnosis
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according to the following definitions; men who did not fulfil these
were excluded:Randomised Treatment1. A
cohort choice cohortMif therewere twoormore PSA tests and no radical treatment in the
12 mo following diagnosisMedian age in years (Q1, Q3), n2. Surgery (RP) if RP was carried out within 12 mo following diagnosisActive monitoring 63 (59, 67), 628 63 (59, 66), 5073. RSurgery 62 (58, 66), 488 62 (58, 65), 262
Radiotherapy 62 (58, 66), 491 63 (59, 66), 189
Managerial occupation (%)
Active monitoring 260/621 (42) 256/496 (52)
Surgery 207/482 (43) 142/259 (55)
Radiotherapy 204/482 (42) 91/186 (49)
Median PSA in ng/ml (Q1, Q3), n
Active monitoring 4.4 (3.6, 6.4), 628 4.6 (3.5, 6.5), 507
Surgery 4.7 (3.7, 6.9), 488 4.9 (3.7, 6.8), 262
Radiotherapy 4.7 (3.7, 6.9), 491 5.0 (3.8, 7.3), 189
PSA >10 ng/ml (%)
Active monitoring 53/628 (8.4) 34/507 (6.7)
Surgery 41/488 (8.4) 26/262 (9.9)
Radiotherapy 51/491 (10) 28/189 (15)
Gleason grade group 1 (%)
Active monitoring 503/628 (80) 417/507 (82)
Surgery 366/488 (75) 186/262 (71)
Radiotherapy 370/491 (75) 123/189 (65)
Gleason grade group 3 and higher (%)
Active monitoring 30/628 (4.8) 17/507 (3.4)
Surgery 27/488 (5.5) 18/262 (6.9)
Radiotherapy 42/491 (8.6) 14/189 (7.4)
Clinical stage T2 (%)
Active monitoring 137/628 (22) 108/507 (21)
Surgery 127/488 (26) 70/261 (27)
Radiotherapy 121/491 (25) 50/189 (26.5)
Low-risk disease (%)a
Active monitoring 409/580 (71) 352/473 (74)
Surgery 293/447 (66) 146/239 (61)
Radiotherapy 298/451 (66) 88/171 (51)
PSA = prostate-specific antigen.
a For approximately 8% of menwith T2 disease, no information was available
on whether their tumour stage was T2a, T2b, or T2c, preventing risk
categorisation according to the D’Amico scheme; these men are omitted for
this measure.T if treatment protocol was started within 12 mo and completed
within 15 mo; men who underwent brachytherapy within 12 mo of
diagnosis were included in the RT arm
Follow-up was standardised according to treatment-specific path-
ways. In all groups, ADT was offered when serum PSA reached a
concentration of 20 mg/l (or less if clinically indicated). Skeletal imaging
was carried out if PSA was 10 mg/l.
2.3. Outcomes
Cause of death was determined as previously reported [2]. Metastatic
disease was defined as bony, visceral, or lymph node metastases, or PSA
levels above 100mg/l. Progression included metastases, clinical T3 or T4
disease, long-term ADT, ureteric obstruction, rectal fistula, or need for
urinary catheter due local tumour growth. Initiation of ADT is presented
separately as a more objective marker of disease progression.
Cancer grades were classified into the following Gleason grade
groups: (1) 3 + 3 = 6; (2) 3 + 4 = 7; (3) 4 + 3 = 7; (4) 4 + 4 = 8, 3 + 5 = 8, 5
+ 3 = 8; and (5) 9. We combined the prognostic factors into a single
“D’Amico” score: men in Gleason grade group 1, with PSA 10 mg/l, and
having clinical stage T2a were of low risk [12–14].
Health-related quality of life impacts on urinary, bowel, and sexual
function were assessed using patient-reported outcome measures
(PROMs) including the Expanded Prostate Index Composite (EPIC [15])
and the International Continence Society Male Short Form (ICSmaleSF
[16]). We present these two PROMs completed at recruitment, 6 mo, and
annually following randomisation; urinary incontinencewas assessed by
daily pad use over the preceding 4wk (EPIC), nocturia two ormore times
per night (ICSmaleSF), potency (EPIC), and blood in stools at least half the
time (EPIC). ICSmaleSF was included during the entire course of the trial
and the EPIC instrument was used from 2005.
2.4. Statistical analysis
The analysis plan included a secondary analysis of the randomised cohort
based on treatment received [17]. This prespecified secondary analysis
accommodated multiple testing: if an overall test of event rates across
the three groups gave evidence of a difference, this was followed by
pairwise tests of RP versus AM and RT versus AM. The other analyses
presented in this paper should be considered exploratory.
We compared outcome event rates using proportional hazard
regression, with two propensity scores included as covariates. Methods
based on the complier average causal effect approach offer better control
of confounding by indication, as they control by known and unknown
prognostic factors. We used a propensity score approach because it was
straightforward generalisation for comparisons between three groups,
we could use the samemethod for the randomised and treatment choice
cohorts, and it was difficult to apply the prespecified instrumental
variablemethods in the current context of complexmovements between
treatments and the absence of a “usual care” control group.
The propensity score approach was applied to both the randomised
and the choice cohort for treatment received. The propensity scoreswere
generated using multinomial logistic regression, with treatment
received as the three-category outcome variable, and the following
covariates: cT stage (1 or 2), Gleason grade group (1, 2, 3, and >3 [4 and5 combined]), log-transformed PSA, age in years, and study centre. The
scoreswere generated for eachman from themodel-fitted values, to give
probabilities of undergoing RP rather than AM and RT, and the
probability of undergoing RT rather than AM and RP.
Hazard ratios for comparisons between RP and AM, and between RT
and AM are presented for the randomised and treatment choice cohorts.
The time scale started on the day of allocation. By definition, men in
treatment-received groups cannot have an (outcome) event between
diagnosis andmeeting the group criteria; consequently, men became “at
risk” at the second PSA test in the AM group, on the day of surgery in the
RP group, and on the 1st day of the protocol in the RT group.
The weighted mean for each treatment comparison is presented
(“pooled” estimate) with weighting by the inverse of the variance of the
estimates (“fixed-effect”meta-analysis). Data from the two cohorts were
combined, and survival curves for prostate cancer mortality and
metastasis calculated from the nonparametric baseline hazard estimate
of proportional hazard regression models, each model having an
additional covariate to distinguish between the randomised and choice
cohorts.
For the PROMs, data from the cohorts were combined, and all data
after treatment were compared between treatment groups; a likelihood-
ratio test quantified evidence against the null hypothesis of equal
response over 6 yr of follow-up across the three treatment groups. Two-
[(Fig._1)TD$FIG]
Fig. 1 – Amongst men who were managed on active monitoring with at least two PSA measurements within 12 mo following diagnosis, the Kaplan-
Meier estimates of cumulative probability of moving to a radical treatment subsequent to the second PSA test (time zero) in the randomised cohort
(solid red line, n = 628) and the choice cohort (dashed blue line, n = 507). PSA = prostate-specific antigen.
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assessments, with Gaussian distributed random effects. All models
included the same propensity measures employed in the analyisis of the
clinical event outcomes, and an additional covariate distinguishing men
in the randomised and choice cohorts. Missing data were not imputed;
all data frommenwith at least onemeasure availablewere included. The
random-effect models provided unbiased estimates of treatment
comparisons, on the assumption that any systematic determinant of
missing data was predictable from the covariates in the model, such as
treatment group or earlier measures of outcome (ie, data were “missing
at random”) [18]. All analyses were performed with Stata software,
version 15.1 (StataCorp, College Station, TX, USA).
3. Results
Of the 1643menwho agreed to randomisation (randomised
cohort), 1260 (78%) received the allocated treatment; the
remaining men chose other treatments. The 997 men who
declined randomisation and chose treatments (treatmentchoice cohort: AM 507 [51%], RP 262 [26%], RT per protocol
125 [13%], other RT including brachytherapy 64 [6%], and
39 other treatments or no treatments completed within the
predefined time limits).
In the randomised cohort, 628 men were managed by
AM, undergoing at least two PSA tests in their first 12 mo of
monitoring. These men remained on monitoring for a
median of 7.7 yr (90% range 1.8–13.1 yr) and underwent a
median of 3.3 tests per year (90% range 2.1–4.7 tests per
year). In the treatment choice cohort, 507 men underwent
at least two PSA tests in their first 12 mo of monitoring, and
were comparable with men in the randomised cohort in
remaining on monitoring for a median of 7.5 yr (90% range
1.7–13.1 yr) and undergoing a median of 3.2 tests per year
(90% range 2.0–4.6 tests per year). It is clear that in both
cohorts, the vast majority of men managed by AM were
undergoing more than the minimum of one PSA test every
12 mo.
Table 2 – For men in the randomised cohort, clinical outcomes for groups defined by random allocation (ie, an intention-to-treat analysis),
and for men in the randomised cohort and treatment choice cohort, clinical outcomes for groups defined by treatment received
Treatment group as defined in the first column
Events/N (rate/1000 person years)
p valuea
Active monitoring Surgery Radiotherapy
Prostate cancer death—randomised cohort
Randomised groups 8/545 (1.5) 5/553 (0.92) 4/545 (0.75) 0.50
Treatment receivedb 11/628 (1.8) 2/488 (0.43) 4/491 (0.85) 0.08
Prostate cancer death—treatment choice cohort
Treatment received 10/507 (2.2) 3/262 (1.2) 1/189 (0.57) 0.05
Metastatic disease or prostate cancer death—randomised cohort
Randomised groups 33/545 (6.1) 13/553 (2.4) 16/545 (3.0) 0.004
Treatment received 36/628 (6.0) 10/488 (2.2) 15/491 (3.2) 0.001
Metastatic disease or prostate cancer death—treatment choice cohort
Treatment received 28/507 (6.1) 8/262 (3.3) 3/189 (1.7) <0.001
Disease progression—randomised cohort
Randomised groups 112/545 (20) 46/553 (8.5) 46/545 (8.6) <0.001
Treatment received 142/628 (24) 26/488 (5.6) 30/491 (6.3) <0.001
Disease progression—treatment choice cohort
Treatment received 79/507 (17) 18/262 (7.5) 15/189 (8.5) <0.001
Hormone treatment—randomised cohort
Randomised groups 47/545 (8.7) 26/553 (4.8) 30/545 (5.6) 0.024
Treatment received 53/628 (8.8) 22/488 (4.8) 25/491 (5.3) 0.002
Hormone treatment—treatment choice cohort
Treatment received 30/507 (6.5) 11/262 (4.6) 11/189 (6.2) 0.19
All death—randomised cohort
Randomised groups 59/545 (11) 55/553 (10) 55/545 (10) 0.87
Treatment received 64/628 (11) 45/488 (9.7) 55/491 (12) 0.90
All death—treatment choice cohort
Treatment received 54/507 (12) 23/262 (9.6) 17/189 (9.6) 0.41
a All p values are for a test of the null hypothesis “equal outcome across the three treatment groups”, calculated using proportional hazard regression including
the two propensity scores as covariates.
b This is a prespecified secondary analysis.
Table 3 – Estimated hazard ratios comparing each pair of treatments in turn: the groups are defined by “treatment received” with
adjustment by propensity score to reduce confounding by indication
Surgery versus active
monitoring
Radiotherapy versus active
monitoring
Radiotherapy versus surgery
Hazard ratio
(95% confidence
interval)
p value Hazard ratio
(95% confidence
interval)
p value Hazard ratio
(95% confidence
interval)
p value
Prostate cancer death
Randomised cohort 0.24 (0.05, 1.07) 0.45 (0.14, 1.41) 1.89 (0.34,10.38)
Treatment choice cohort 0.39 (0.10, 1.49) 0.14 (0.02, 1.15) 0.35 (0.03, 3.59)
Pooled estimate 0.32 (0.12, 0.87) 0.026 0.34 (0.12, 0.92) 0.034 1.07 (0.27, 4.30) 0.9
Metastatic disease or prostate cancer death
Randomised cohort 0.31 (0.16, 0.64) 0.48 (0.26, 0.89) 1.54 (0.69, 3.43)
Treatment choice cohort 0.35 (0.15, 0.78) 0.18 (0.05, 0.62) 0.52 (0.13, 2.03)
Pooled estimate 0.33 (0.19, 0.55) <0.001 0.40 (0.23, 0.69) 0.001 1.17 (0.59, 2.34) 0.7
Disease progression
Randomised cohort 0.19 (0.12, 0.29) 0.20 (0.13, 0.29) 1.05 (0.62, 1.78)
Treatment choice cohort 0.31 (0.18, 0.53) 0.32 (0.18, 0.57) 1.04 (0.51, 2.09)
Pooled estimate 0.23 (0.16, 0.33) <0.001 0.23 (0.17, 0.32) <0.001 1.05 (0.69, 1.60) 0.8
Hormone treatment
Randomised cohort 0.47 (0.28, 0.77) 0.51 (0.32, 0.83) 1.09 (0.61, 1.95)
Treatment choice cohort 0.54 (0.26, 1.09) 0.73 (0.35, 1.50) 1.36 (0.57, 3.26)
Pooled estimate 0.49 (0.33, 0.74) 0.001 0.57 (0.38, 0.85) 0.005 1.17 (0.72, 1.89) 0.5
All death
Randomised cohort 0.97 (0.66, 1.42) 1.06 (0.74, 1.52) 1.09 (0.74, 1.63)
Treatment choice cohort 0.77 (0.46, 1.28) 0.73 (0.42, 1.29) 0.95 (0.49, 1.82)
Pooled estimate 0.89 (0.66, 1.21) 0.5 0.95 (0.70, 1.29) 0.7 1.05 (0.75, 1.47) 0.8
Estimates for the randomised and treatment choice cohorts are combined as a “pooled estimate”.
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Fig. 2 – Prostate cancer-specific survival curves (derived from the proportional hazard regression model) for groups defined by receiving active
monitoring (green), surgery (red), and radiotherapy (blue), with corresponding groups combined across randomised and treatment choice cohorts.
E U RO P E AN U RO LOGY 7 7 ( 2 0 2 0 ) 3 2 0 – 3 3 0 325Baseline characteristics of men in each of the groups are
shown in Table 1 (with all Gleason grade groups presented
in Supplementary Table 1). The vast majority underwent
one of the study treatments as defined previously, with just
36/1643 (2.2%) and 39/997 (3.9%) of men in the randomised
and choice cohorts, respectively, not included in the three
defined treatment groups. The two cohorts differed in a
greater proportion of men in managerial occupations in the
choice cohort. Selection biases were evident, withmenwith
higher-risk grade and stage disease being more likely to
undergo radical treatments than AM [7].
Fig. 1 presents the Kaplan-Meier estimate of the
probability of moving to radical treatment from AM over
a median of 10 yr. Very similar rates were observed in the
randomised and treatment choice cohorts, with around 45%
of men in both having moved to radical treatment within
10 years.
Table 2 includes clinical outcomes for randomly allocat-
ed groups with the initial ITT comparison adjusted for thepropensity scores. Outcomes are then presented for
treatment-received groups in both the randomised and
the choice cohort. While absolute differences are small,
there is strong evidence of increased metastatic disease,
disease progression, and initiation of ADT for AM compared
with surgery and RT. The risks of disease-specific and all-
cause death remain lowand consistentwith chance. Risks of
these adverse clinical outcomes for treatment received in
both the randomised and the choice cohort are similar, the
exceptions being lower rates of disease progression and ADT
in the treatment-choice group managed by AM. Supple-
mentary Table 2 presents clinical outcomes by treatment-
received group and Gleason grade group at diagnosis.
Most progression was development of a high stage (T3 or
T4) or starting of ADT, and was higher in the AM group (60%
[85/142] in the randomised cohort and 57% [45/79] in the
choice cohort). Thepresence of stage T3 or T4did not prevent
subsequent radical treatment in some men, with 20%
(22/112) undergoing RP and 35% (39/112) undergoing RT.
[(Fig._3)TD$FIG]
Fig. 3 – Proportions free of metastatic disease (derived from the proportional hazard regression model) for groups defined by receiving active
monitoring (green), surgery (red), and radiotherapy (blue), with corresponding groups combined across randomised and treatment choice cohorts.
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received in the randomised and choice cohorts separately,
with the corresponding results from the two cohorts then
being pooled. The pooled estimates indicate strong
evidence that surgery and RT, each in comparison with
AM, reduce the incidence of prostate cancer death (Fig. 2),
metastatic disease (Fig. 3), disease progression, and the
onset of hormone treatment. There was no evidence that
either surgery or RT compared with AM reduced all-cause
death, nor evidence of a difference on any of the five
outcome measures when comparing surgery with RT.
In exploratory analyses, we combined the surgery group
and the RT treatment-received group, and compared
outcomes with AM. There was a reduction in prostate
cancer-specific mortality with radical treatment compared
with AM in the randomised cohort (hazard ratio = 0.34; 95%
confidence interval [CI] 0.13, 0.94) and the treatment choice
cohort (hazard ratio = 0.27; 95% CI 0.08, 0.91). Pooling of
these two estimates suggested a marked decrease in
prostate cancer mortality with radical treatment (hazardratio = 0.31; 95% CI 0.14, 0.67; p = 0.003), although the small
number of prostate cancer deaths means that the absolute
reduction is modest.
Urinary incontinence, as measured by patient-reported
pad use, was increased following surgery compared with
AM and RT (p < 0.001; Fig. 4 and Supplementary Table 3).
Six months after surgery, 55% reported daily use of pads,
reducing to 20% after 3 yr and remaining stable thereafter.
Pad use was negligible following RT but increased gradually
to 7% in the AM group. An increased proportion of men
reported nocturia in the 6 mo following RT (65%) before
stabilising at 30–40% for all men irrespective of manage-
ment (p < 0.001; Fig. 4 and Supplementary Table 4). RT and
surgery both reduced the proportion of men reporting
potency at 6 mo (18.5% and 5%, respectively). Although
there was some recovery by 2 yr, only 28–30% of men in the
RT group and 15% in the surgery group reported being
potent at 6 yr (p < 0.001; Fig. 4 and Supplementary Table 5).
More men in the AM group reported themselves as potent,
but this reduced gradually over time, reflecting ageing and
[(Fig._4)TD$FIG]
Fig. 4 – Patient-reported incontinence pad use, nocturia, potency,
and bloody stools by active monitoring (green dash), radical
prostatectomy (red), and radiotherapy (blue) groups, defined
by treatment received. EPIC = Expanded Prostate Index
Composite; ICSmaleSF = International Continence Society Male
Short Form.
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a small proportion of men (around 5%) experienced bloody
stools at least half the time,with this proportionmaintained
over the 6-yr follow-up (p < 0.001; Fig. 4 and Supplemen-
tary Table 6).4. Discussion
The analysis presented here compares groups according to
treatment received in two cohorts within a trial with
uniform initial recruitment: the randomised cohort that
initially agreed to randomisation, and the treatment choice
cohort that was eligible but declined randomisation and
chose treatment. For the prespecified comparison of groups
defined by treatment received within the randomised
cohort, we found no evidence of a difference in prostate
cancer death between the three treatments at a median
follow-up of 10 yr, which is in accord with the primary ITT
analysis [2].
The exploratory analyses comparing outcomes be-
tween groups defined by treatment received, in the
combined and treatment choice cohorts, gave results that
were in broad agreement with the ITT analysis [2]. How-
ever, when the outcomes for the two cohorts were pooled,
there was evidence of a lower risk of prostate cancer
death following surgery and RT compared with AM,
although the absolute reduction in prostate cancer deaths
with radical treatment was modest. However, recent
studies suggest that the use of metastasis-free survival is
a highly appropriate endpoint for prostate cancer trials
[19–21]; studies with both the ITT and this comparison of
groups defined by treatment received confirmed the
increased rates of metastasis-free survival in the two
radical treatment arms.
The four PROMs presented in this paper lead to the
same conclusions as the ITT analysis [3], with the
results being clearer. There was strong evidence of
substantial and persistent elevations in the rates of
urinary incontinence and erectile dysfunction following
surgery, in the rates of nocturia in the 12 mo following RT,
and in the rates of erectile dysfunction and bloody stools
following RT. Men managed by AM avoided the impacts
caused by radical treatments, although slow and
gradual increases in urinary incontinence, nocturia, and
erectile dysfunction were reported during follow-up,
reflecting ageing and increased receipt of radical treat-
ments over time. We have previously noted the “trade-
off” that men with localised prostate cancer need to make
between side effects on urinary, bowel, and sexual
function, against reducing later risks of metastasis and
progression, and resulting impacts on quality and length
of life [2,3].
The key limitation to analyses based on treatment
received rather than ITT is the potential for bias. Such
groups will differ in terms of occupation, and prognostic
factors that influence clinicians to advise patients to
E U RO P E AN URO L OGY 7 7 ( 2 0 2 0 ) 3 2 0 – 3 3 0328undergo specific treatments. In both the randomised and
the treatment choice cohort, there was evidence that men
with higher-risk disease were more likely to be managed by
radical treatments and lower-risk men by AM [7]. However,
despite such selection biases, clinical outcomes were worse
in the AM group.
We employed propensity score methods to control for
confounding due to imbalance in known prognostic
factors. However, such approaches do not control for
unknown factors, although confidence in the results
reported here is increased by three factors. Firstly, the
similarity with the primary ITT analysis from the RCT.
Secondly, the direction of confounding by known prognos-
tic factors (eg, patients with low-risk disease were more
likely to be managed by AM) means that known
confounding cannot explain increased prostate cancer-
related events in the AM group. Thirdly, all-cause death
rates are comparable across the three treatment-received
groups, suggesting that a man's general health did not
underlie the selection biases.
A second limitation results from the natural history of
screen-detected and localised prostate cancer, requiring
studies with many years of follow-up during
which clinical practice evolves. Evaluation of men for
AM has developed, largely driven by changes in the
diagnostic pathway, which uses prebiopsy imaging using
multiparametric magnetic resonance imaging (mpMRI)
scanning, transperineal biopsy, and targeting of visible
lesions. This will likely lead to a reduction in the diagnosis
of low-risk, low-volume prostate cancer and an increase in
the diagnosis of significant cancers requiring early
intervention [22,23].
The CAP trial of a single screening round using PSA
testing demonstrated that conventional diagnostic path-
ways miss cancers destined to be lethal. Many such men
have PSA levels below the conventional threshold for
referral, while diagnosing many low-risk tumours [24]. In
addition, the results of AM reported here may reflect that
some men choosing or being randomised to AM may not
have been recommended for this option on the basis of
current management that would include mpMRI [23]. De-
spite this limitation, and the low intensity of monitoring
primarily by PSA kinetics, mortality from prostate cancer
remained very low. Rates of change of management to
radical treatments in both ProtecT cohorts were in keeping
with previous active surveillance programmes reporting
approximately 30% of men receiving radical treatment
within 3 yr [25,26].
Treatments for progressing prostate cancer have also
improved markedly in recent years, and it is likely that this
has also contributed to the low prostate cancer mortality
rates observed in the trial [27].
5. Conclusions
The ProtecT primary ITT analysis, and analyses of the
randomised and treatment received cohorts according to
treatment received have confirmed that surgery and RTreduce metastasis and progression compared with AM, but
impact sexual, urinary, and bowel functioning. In addition,
exploratory analyses suggest that radical treatmentsmay be
associated with lower prostate cancer mortality than AM,
albeit the numbers of such deaths were low irrespective of
treatment. The findings need to be considered in the context
of potential biases and confounding variables in the
treatment received analysis. Follow-up of these cohorts is
continuing and will clarify further the various trade-offs
that need to be weighed up when choosing treatment for
localised prostate cancer.
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